VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 464 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2014. The put-call ratio across all filers is 1.12 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $9,205,000 | -69.8% | 350,000 | +16.7% | 3.26% | -51.6% |
| Q4 2015 | $30,495,000 | -46.2% | 300,000 | -5.5% | 6.74% | -45.6% |
| Q3 2015 | $56,647,000 | -75.4% | 317,561 | -69.4% | 12.38% | -43.7% |
| Q2 2015 | $230,599,000 | +11.8% | 1,038,033 | -0.0% | 21.97% | -24.2% |
| Q1 2015 | $206,241,000 | +109.4% | 1,038,371 | +50.8% | 28.99% | +2.9% |
| Q4 2014 | $98,513,000 | +60.3% | 688,371 | +47.0% | 28.16% | +148.7% |
| Q3 2014 | $61,450,000 | -33.4% | 468,371 | -36.0% | 11.32% | -13.5% |
| Q2 2014 | $92,315,000 | +24.5% | 731,960 | +30.2% | 13.09% | -27.6% |
| Q1 2014 | $74,127,000 | +33.2% | 562,293 | +18.6% | 18.09% | +33.6% |
| Q4 2013 | $55,666,000 | -12.5% | 474,158 | -22.2% | 13.53% | -28.4% |
| Q3 2013 | $63,612,000 | +60.9% | 609,718 | +38.3% | 18.89% | -4.0% |
| Q2 2013 | $39,535,000 | – | 440,883 | – | 19.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |